These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21098757)

  • 1. Analysis of pharmaceutical safety-related regulatory actions in Japan: do tradeoffs exist between safer drugs and launch delay?
    Yamada T; Kusama M; Hirai Y; Arnold F; Sugiyama Y; Ono S
    Ann Pharmacother; 2010 Dec; 44(12):1976-85. PubMed ID: 21098757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 3. Factors associated with spontaneous reporting of adverse drug reactions in Japan.
    Yamada T; Watanabe Y; Kusama M; Sugiyama Y; Ono S
    Pharmacoepidemiol Drug Saf; 2013 May; 22(5):468-76. PubMed ID: 23172714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hasty approval, more withdrawals.
    Prescrire Int; 2005 Aug; 14(78):144. PubMed ID: 16106597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opening Pandora's pillbox: using modern information tools to improve drug safety.
    Gottlieb S
    Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 7. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit-risk assessment: to quantify or not to quantify, that is the question.
    Yuan Z; Levitan B; Berlin JA
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):653-6. PubMed ID: 21538675
    [No Abstract]   [Full Text] [Related]  

  • 9. Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization.
    O'Neill RT
    Stat Med; 1995 May 15-30; 14(9-10):117-27. PubMed ID: 7569506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between Japan and the United States in dosages of drugs recently approved in Japan.
    Nakashima K; Narukawa M; Kanazu Y; Takeuchi M
    J Clin Pharmacol; 2011 Apr; 51(4):549-60. PubMed ID: 20628171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beware of new drugs, study suggests.
    Levenson D
    Rep Med Guidel Outcomes Res; 2002 May; 13(10):1-2, 5. PubMed ID: 12492085
    [No Abstract]   [Full Text] [Related]  

  • 12. The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.
    Danzon PM; Wang YR; Wang L
    Health Econ; 2005 Mar; 14(3):269-92. PubMed ID: 15386651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Safety-Related Regulatory Actions for New Drugs in Japan by Nature of Identified Risks.
    Fujikawa M; Ono S
    Pharmaceut Med; 2017; 31(5):317-327. PubMed ID: 29056852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The challenges of immunogenicity in developing biosimilar products.
    Wadhwa M; Thorpe R
    IDrugs; 2009 Jul; 12(7):440-4. PubMed ID: 19579165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Participation to international registration trials--from the investigator's standpoint].
    Ohtsu A
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):297-300. PubMed ID: 17301548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of drug repositioning in the current pharmaceutical market.
    Tobinick EL
    Drug News Perspect; 2009 Mar; 22(2):119-25. PubMed ID: 19330170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug safety--important to us all!
    Böttiger LE
    J Intern Med; 2001 Oct; 250(4):269-70. PubMed ID: 11576314
    [No Abstract]   [Full Text] [Related]  

  • 18. Short patent lives jeopardize drug and patient safety.
    Hondeghem LM; De Clerck F; Camm J
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could conditional release of new drugs provide the information required to study drug effectiveness? - A discussion paper.
    Rawson NS; West R; Appel WC
    Can J Clin Pharmacol; 2000; 7(4):185-90. PubMed ID: 11118964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drug approval times and clinical evidence in Japan.
    Ono S; Yoshioka C; Asaka O; Tamura K; Shibata T; Saito K
    Contemp Clin Trials; 2005 Dec; 26(6):660-72. PubMed ID: 16122988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.